The week in pharma: action, reaction and insight – week to February 3, 2023

By Barbara Obstoj-Cardwell. Editor

Last Tuesday, Dutch gene therapy company uniQure announced a licensing deal with US start-up Apic Bio relating to the latter’s APB-102 to expand its pipeline of gene therapies for neurological disorders. In a heavy week for fourth-quarter and full-year financial results, Pfizer reported record-breaking figures, but warned that the covid factor is receding and that means lower sales and earnings from Comirnaty and Paxlovid. Fellow US fellow pharma major Eli Lilly, posted a down turn in revenues, with disappointing sales of obesity drug Mounjaro. Amgen launched its Amjevita in the USA, marking the first biosimilar to AbbVie’ mega-blockbuster Humira in the all-important American market and opening the floodgates to more copies.

uniQure pipeline bolstered with Phase I/II-ready SOD1 ALS GTx